FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Immune Design
Syndicate content

Immune Design recruits former Elan exec

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Former Elan president Carlos Paya has signed on as Immune Design's new CEO. The Seattle-based vaccine developer, which was founded in 2008, is developing therapeutic vaccines for the treatment of infectious and malignant disease. Xconomy reports that the company has already raised $50 million in venture capital and inked a partnership deal with AstraZeneca's Medimmune. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Immune Design  

Comments

Post a comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.